Abstract:Our appreciation of mitochondrial disease, in the context of both genetic and phenotypic heterogeneity, has blossomed over recent years with successive epidemiological studies, accrued clinical expertise and scientific advances. Epidemiological studies have encountered numerous obstacles, most importantly the initial recognition and diagnosis of a rare and variable multisystem disorder, but also complex referral pathways, specific and evolving diagnostic techniques, impaired penetrance and heteroplasmic mtDNA mutations, and the potential for ascertainment bias in disease cohorts. These inherent difficulties have contributed to both historical over- and under-representation of specific mtDNA or nuclear DNA-related mitochondrial disease. The last three decades have seen over 250 pathogenic mtDNA mutations identified, and the evolution of whole-genome sequencing is now identifying increasing numbers of pathogenic nuclear disease genes. Only recently has it been possible to estimate the prevalence of disease due to mutations of both the nuclear and mitochondrial genomes. To date, the most detailed prevalence figures available report the number of adults suffering from all forms of mitochondrial disease to be in the region of 12.5 per 100,000 of the population. One in 4300 people (23 per 100,000) carry pathogenic mutations of either nuclear or mtDNA and either have disease or are at risk of disease in the future. The most prevalent single mutation to cause mitochondrial disease is now recognised to be due to the m.3243A>G mutation in the MT-TL1 gene with a disease estimation of 3.5 per 100,000. Childhood-onset mitochondrial disease has been predicted to range from 0.5 to 1.5 cases per 100,000, approximately one-tenth of that seen in adults. Although no true population-based prevalence studies have yet been performed using laborious whole-genome sequencing, most existing studies focus on screening for individual mutations within cohorts felt to represent either the general population or the particular disease-defined cohorts. A small number of specific mtDNA mutations have been identified as causing a proportion of disease in diabetes, deafness and optic neuropathy cohorts. Although often considered a hallmark of mitochondrial disease, the prevalence of diabetes in most forms of mitochondrial disease is no higher than 10–12% as compared with a prevalence in the general population of 4.5%. The recognised association can be mainly attributed to the prevalent m.3243A>G mutation which frequently presents with maternally inherited deafness and diabetes. Deafness is common among many mtDNA mutations, usually as part of a broader phenotype, but can be the sole manifestation in the m.1555A>G mutation, particularly following exposure to aminoglycoside antibiotics. Leber’s hereditary optic neuropathy (LHON) occurs as a result of three common mutations in 90% of affected patients, with the point prevalence of disease standing at 3.7 per 100,000.The provision and development of highly specialised services, prospective cohort studies and use of objective clinical rating scales have contributed heavily to our understanding of the mitochondrial disorders today, and are likely to be instrumental in achieving more accurate epidemiological studies in mitochondrial disease in the future.

Known genes, new genes and new phenotypes in mitochondrial eye diseases

[The Influence of Mitochondrial Haplogroup on Leber's Hereditary Optic Neuropathy].

Mitochondria and the eye—manifestations of mitochondrial diseases and their management

Molecular Pathogenetic Mechanism of Leber's Hereditary Optic Neuropathy

[Leber's Hereditary Optic Neuropathy May Be Associated with the Mitochondrial Trnaglu A14693G Mutation in Three Chinese Families].

Mitochondrial Variants May Influence the Phenotypic Manifestation of Leber'S Hereditary Optic Neuropathy-Associated Nd4 G11778a Mutation

The Role of Mitochondrial Dysfunction in Hereditary Optic Neuropathy

Leber’s Hereditary Optic Neuropathy is Associated with Mitochondrial ND6 T14502C Mutation

Biallelic Mutations in the Ferredoxin Reductase Gene Cause Novel Mitochondriopathy with Optic Atrophy

Mitochondria and vision – a life in mitochondria always on the move

Recent advances in understanding the molecular genetic basis of mitochondrial disease

Genetic basis of mitochondrial diseases

Epidemiology of Mitochondrial Disease

The mitochondrial <I>ND5</I> T12338C mutation may be associ-ated with Leber’s hereditary optic neuropathy in two Chinese fami-lies

Mitophagy: An Emerging Target in Ocular Pathology

Mitochondrial Genome Study Identifies Association Between Primary Open-Angle Glaucoma and Variants in MT-CYB, MT-ND4 Genes and Haplogroups

Massively parallel sequencing of mitochondrial genome in primary open angle glaucoma identifies somatically acquired mitochondrial mutations in ocular tissue

The genetic landscape of mitochondrial diseases in the next-generation sequencing era: a Portuguese cohort study

Optic neuropathies: the tip of the neurodegeneration iceberg

Variants in mitochondrial disease genes are common causes of inherited peripheral neuropathies

Association between glaucoma susceptibility with combined defects in mitochondrial oxidative phosphorylation and fatty acid beta oxidation